t-AUCB Improves Endothelial Function and Maintains Liver-Kidney Function in Mouse Model of Polymicrobial Sepsis
Endothelial dysfunction associated with multiple organ failure predominantly leads to poor prognosis and high mortality in septic patients. Stabilisation of epoxyeicosatrienoic acids (EETs) levels via inhibiting their breakdown by the soluble epoxide hydrolase (sEH) enzyme was reported to be beneficial in various inflammatory conditions. The current investigation elucidates the impact of in vivo administration of t-AUCB (a potent sEH inhibitor) on endothelium-dependent and -independent vasorelaxation in the mouse aorta, along with its impact on liver-kidney biomarkers in septic mice. Marked endothelial dysfunction, as evidenced by a reduction in relaxant response to acetylcholine (ACh) was found in septic mice, while endothelial-independent relaxation to sodium nitroprusside (SNP) remains unaltered. Significantly elevated serum levels of liver and kidney biomarkers like alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine in septic mice as compared to SO mice were found. Treatment of septic mice with t-AUCB and/or with imipenem (IMI) improved endothelial vasorelaxation to ACh, while endothelium-independent vasorelaxation to SNP remained unaltered. Further, t-AUCB alone and/or with IMI also restored the elevated levels of liver and kidney biomarkers. Thus, the sEH inhibitor, t-AUCB, helps to improve vascular endothelial dysfunction and consequently liver and kidney dysfunction in sepsis, possibly via regulating circulatory perfusion. Major Findings: sEH inhibitor, t-AUCB, improves endothelial function and exerts organ protective effect in sepsis possibly by regulating circulatory perfusion and inflammatory cascade.